| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10221275 | The Journal of Arthroplasty | 2018 | 42 Pages |
Abstract
Strong evidence supports the use of TXA to reduce blood loss and risk of transfusion after primary THA. No specific routes of administration, dosage, dosing regimen, or time of administration provides clearly superior blood-sparing properties.
Related Topics
Health Sciences
Medicine and Dentistry
Orthopedics, Sports Medicine and Rehabilitation
Authors
Yale A. MD, Dipak B. MD, David S. MD, MBA, Adolph J. MD, Peter MPH, Kyle MPH, Stefano A. MD, Henry D. MD, Emil MD, Rebecca L. MD, Stavros G. MD, PhD, Siraj A. MD, Alexander P. MD, Craig J. MD,